


JAMA Ophthalmology Clinical Challenge

A Young Boy With Changes in the Retinal Pigment Epithelium

Ashley Lopez-Cañizares, MS; Piero Carletti, BS; Audina M. Berrocal, MD

A Fluorescein angiogram



B Color fundus photograph



Figure 1. Fluorescein angiogram and color fundus photograph. A, Fluorescein angiography of the left eye revealed a circular area of hypofluorescence encompassing the macula (white arrowheads) and an irregular fovea (blue arrowhead), likely representing a thickened choroid secondary to a horizontal papillomacular fold. B, Color fundus photograph disclosed peripheral retinal pigment epithelium mottling (white arrowheads) and a densely pigmented small macula (blue arrowhead).

A 9-year-old boy was referred to a pediatric retina specialist for evaluation of changes in the peripheral retinal pigment epithelium. Ocular history included high hyperopia and amblyopia, and abnormal foveal contour was discovered when he was aged 3 years. Family history was noncontributory. Best-corrected visual acuity was 20/50 in the right eye and 20/30 in the left. Pupils were round and reactive to light, and intraocular pressure and anterior segment examination were within normal limits. Dilated fundus examination revealed blunted foveal reflexes and abnormal vasculature in the inferonasal quadrant of the right eye. Fluorescein angiography displayed symmetric bilateral circular areas of hypofluorescence around the macula and irregular fovea with no leakage (**Figure 1A**). Color fundus photography showed symmetric bilateral mottling of the retinal pigment epithelium in the periphery (**Figure 1B**). Spectral-domain optical coherence tomography on initial examination showed an abnormal foveal contour with loss of the foveal pit and intraretinal cystoid cavities within the inner nuclear layer.

WHAT WOULD YOU DO NEXT?

- A. Perform B-scan ultrasonography
- B. Genetic testing to assess for ocular diseases
- C. Observation
- D. Obtain fundus autofluorescence

[+ Quiz at jamacmelookup.com](#)

Diagnosis

Congenital nanophthalmos

What to Do Next

- B. Genetic testing to assess for ocular diseases

Discussion

Nanophthalmos, which affects ocular development, is the most prevalent genetic congenital ocular disorder.^{1,2} It is characterized phenotypically by small eyes and normally presents without associated structural defects¹ and with high hyperopia secondary to severely decreased

axial length.³ Mean best-corrected visual acuity ranges from 20/25 to 20/50.⁴ Posterior involvement can lead to an irregular fovea (**Figure 1**), papillomacular folds, abnormal foveal contour, and uveal effusions. Patients with nanophthalmos have an increased risk of developing acute angle-closure glaucoma, retinal detachment, and intraretinal cysts (**Figure 2**).² The schisislike cystoid thickening of the retina has been proposed to arise from crowding of the retina and uveal tissues and poor outflow through the characteristically thickened sclera. Although literature on the angiographic characterization of this phenomenon is limited, fundus autofluorescence is not expected to show leakage surrounding these spaces.^{5,6}

Nanophthalmos can be inherited in an autosomal dominant or recessive fashion or from sporadic genetic derangements that interfere with the normal formation of the optic cup.^{1,2} Depending on the presence of ocular and systemic manifestations, nanophthalmos can be isolated, complex, or syndromic.^{2,7} The gene most implicated with nanophthalmos is the membrane-type frizzled-related protein gene (*MFRP*), also associated with retinal dystrophy.^{2,3} *MFRP* encodes for a transmembrane protein highly expressed in the retinal pigment epithelium and ciliary body and plays an important role in eye development prenatally and postnatally, with the only progressive change mentioned in the literature being amblyopia when axial hyperopia is left untreated in nanophthalmos.¹

The genetic etiology of the severe hyperopia in this patient remained unrecognized until he was referred to a pediatric retina specialist to rule out retinitis pigmentosa. At that point, the patient had considerable posterior segment involvement causing abnormal foveal and papillomacular folds, retinal pigment epithelium mottling (Figure 1), and intraretinal cysts (Figure 2). This constellation of findings along with axial lengths of 17.8 mm in the right eye and 17.7 mm in the left eye triggered genetic testing.

Genetics for ocular diseases (B) is the correct answer because other conditions have similar presentation to nanophthalmos, making genetic testing the more certain way to diagnose it. If no mutation is found, this can also help rule out similar-appearing ocular genetic diseases.

Although B-scan ultrasonography (A) would be helpful to confirm decreased axial length, suggestive of nanophthalmos,⁸ it does not provide enough information to rule out other diseases or confirm the diagnosis. Observation (C) alone is not appropriate. Although the findings suggest nanophthalmos, further investigation is needed to diagnose the condition, provide treatment as neces-




Figure 2. Optical coherence tomography of the macula. Spectral-domain optical coherence tomography showed an abnormal foveal contour with loss of the foveal pit (blue arrowhead) and intraretinal cystoid cavities within the inner nuclear layer (white arrowheads).

sary, and be aware of potential complications. Finally, fundus autofluorescence (D) would likely show macular changes associated with the cystoid retinal thickening; however, it would not be enough to make a definitive diagnosis, and genetic testing would still be necessary.²

Patient Outcome

This patient underwent genetic testing revealing 2 pathogenic variants in the *MFRP* gene, confirming the diagnosis of autosomal recessive nanophthalmos and retinal dystrophy. The mother was informed about the condition and its prognosis. The patient underwent amblyopic management, is being monitored biannually, and has remained visually stable.

ARTICLE INFORMATION

Author Affiliations: Bascom Palmer Eye Institute, Miami, Florida.

Corresponding Author: Audina M. Berrocal, MD, Bascom Palmer Eye Institute, 900 NW 17th St, 2nd Floor, Miami, FL 33136 (aberrocal@med.miami.edu).

Published Online: July 21, 2022.
doi:10.1001/jamaophthalmol.2022.1653

Conflict of Interest Disclosures: Dr Berrocal has financial interests in Aerie Pharmaceuticals, ProQR Therapeutics, Oculus Surgical, Alcon, Allergan, Bayer, Dutch Ophthalmic Research Center, Phoenix Clinical, Vizunex Medical Systems, Zeiss, and Novartis. No other disclosures were reported.

Funding/Support: This work was supported by National Institutes of Health Center Core grant P30EY014801, Research to Prevent Blindness unrestricted grant GR004596, and US Department of Defense grant W81XWH-13-1-0048.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or

approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the patient's family for granting permission to publish this information.

REFERENCES

- Sundin OH, Dharmaraj S, Bhutto IA, et al. Developmental basis of nanophthalmos: *MFRP* is required for both prenatal ocular growth and postnatal emmetropization. *Ophthalmic Genet*. 2008;29(1):1-9. <https://pubmed.ncbi.nlm.nih.gov/18363166/> doi:10.1080/13816810701651241
- Almoallem B, Arno G, De Zaeytjij J, et al. The majority of autosomal recessive nanophthalmos and posterior microphthalmia can be attributed to biallelic sequence and structural variants in *MFRP* and *PRSS56*. *Sci Rep*. 2020;10(1):1289. doi:10.1038/s41598-019-57338-2
- Sundin OH, Leppert GS, Silva ED, et al. Extreme hyperopia is the result of null mutations in *MFRP*, which encodes a Frizzled-related protein. *Proc Natl Acad Sci U S A*. 2005;102(27):9553-9558. doi:10.1073/pnas.0501451102
- Okumichi H, Itakura K, Yuasa Y, Fukuto A, Kiuchi Y. Foveal structure in nanophthalmos and visual acuity. *Int Ophthalmol*. 2021;41(3):805-813. doi:10.1007/s10792-020-01633-9
- Dhrami-Gavazi E, Schiff WM, Barile GR. Nanophthalmos and acquired retinoschisis. *Am J Ophthalmol*. 2009;147(1):108-110.e1. doi:10.1016/j.ajo.2008.07.045
- Yu S, Gao Y, Liang X, Huang Y. Acquired retinoschisis resolved after 23Gage pars plana vitrectomy in posterior microphthalmos. *BMC Ophthalmol*. 2014;14:65. doi:10.1186/1471-2415-14-65
- Godinho G, Madeira C, Grangeia A, et al. A novel *MFRP* gene variant in a family with posterior microphthalmos, retinitis pigmentosa, foveoschisis, and foveal hypoplasia. *Ophthalmic Genet*. 2020;41(5):474-479. doi:10.1080/13816810.2020.1795888
- Carricondo PC, Andrade T, Prasov L, Ayres BM, Moroi SE. Nanophthalmos: a review of the clinical spectrum and genetics. *J Ophthalmol*. 2018;2018:2735465. doi:10.1155/2018/2735465